Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

NCT02655770 on ClinicalTrials.gov · last registry update 2021-01-14

Finished December 2019, after enrolling 40 people. Primary outcome, as filed: Change in diastolic properties as assessed by CMR. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Copenhagen University Hospital, Rigshospitalet
Sponsor type: Other
Enrollment: 40
Started: 2016-02
Primary completion: 2019-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in diastolic properties as assessed by CMR.

Conditions studied

Diabetes Mellitus Type 2 · Diastolic Dysfunction · Cardiac MRI · Myocardial Perfusion

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.